New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
09:02 EDTQCORQuestcor's Acthar shows positive results in clinical study
Questcor announced published results from an investigator-initiated clinical study involving two major academic research centers examining the dosing and effectiveness of H.P. Acthar Gel in 20 patients with nephrotic syndrome due to idiopathic membranous nephropathy. The results demonstrate that Acthar can be a potentially useful therapy for inducing remission of proteinuria in patients suffering from nephrotic syndrome secondary to iMN. Acthar was generally well tolerated by patients, with the most common side effects being mood changes, weight gain and transient insomnia.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 15, 2014
06:08 EDTQCORQuestcor implied volatility of 28 at lower end of index mean range
Subscribe for More Information
August 14, 2014
17:21 EDTQCORGulfMark Offshore to replace Questcor in S&P 600 as of 8/18 close
17:16 EDTQCORPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:35 EDTQCORMallinckrodt completes acquisition of Questcor Pharmaceuticals
Subscribe for More Information
13:02 EDTQCORMallinckrodt, Questcor holders approve Mallinckrodt's acquisition of Questcor
Subscribe for More Information
August 8, 2014
07:45 EDTQCORMallinckrodt price target lowered to $77 from $90 at Leerink
Leerink lowered its price target for Mallinckrodt (MNK) shares to $77 citing a heightened risk profile from the Questcor (QCOR) acquisition and significant earnings concentration in Acthar. The firm says it remains on the sidelines with a Market Perform rating on Mallinckrodt.
07:44 EDTQCORMallinckrodt remains favorite specialty pharmaceutical name, says UBS
UBS said Mallinckrodt (MNK) remains its favorite specialty pharmaceutical name following the company's update on its merger with Questcor (QCOR). The firm sees estimates increasing following the close of the transaction, the divestiture of the Medical Imaging division, and the reinvestment in higher margin assets. UBS has a Buy rating with a $94 price target on Mallinckrodt.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use